IL-12B
IL-12B Informations sur la molécule
| Nom anglais | Interleukin-12 subunit beta | Nombre de médicaments commercialisés | 8 |
| Nombre de médicaments cliniques | 2 | Alias de la cible | IL-12B，NK cell stimulatory factor chain 2，IL12B，Interleukin 12B，Interleukin 12B (Natural Killer Cell Stimulatory Factor 2， Cytotoxic Lymphocyte Maturation Factor 2， P40)，Cytotoxic Lymphocyte Maturation Factor 40 KDa Subunit，Interleukin-12 Beta Chain，Interleukin 12， P40，IL12， Subunit P40，CLMF P40，NKSF2，Cytotoxic Lymphocyte Maturation Factor 2， P40，Interleukin-12 Subunit Beta，CLMF2，IMD28，IMD29，CLMF，NKSF，Interleukin-12 Subunit p40，Natural Killer Cell Stimulatory Factor， 40 KD Subunit，IL-12 Subunit P40，Natural Killer Cell Stimulatory Factor-2 |
| Phase de R&D la plus avancée | Approved | ||
| Nom anglais | Interleukin-12 subunit beta |
| Alias de la cible | IL-12B，NK cell stimulatory factor chain 2，IL12B，Interleukin 12B，Interleukin 12B (Natural Killer Cell Stimulatory Factor 2， Cytotoxic Lymphocyte Maturation Factor 2， P40)，Cytotoxic Lymphocyte Maturation Factor 40 KDa Subunit，Interleukin-12 Beta Chain，Interleukin 12， P40，IL12， Subunit P40，CLMF P40，NKSF2，Cytotoxic Lymphocyte Maturation Factor 2， P40，Interleukin-12 Subunit Beta，CLMF2，IMD28，IMD29，CLMF，NKSF，Interleukin-12 Subunit p40，Natural Killer Cell Stimulatory Factor， 40 KD Subunit，IL-12 Subunit P40，Natural Killer Cell Stimulatory Factor-2 |
| Nombre de médicaments commercialisés | 8 |
| Nombre de médicaments cliniques | 2 |
| Phase de R&D la plus avancée | Approved |
IL-12B Liste de produits
- Attribut
Protein (4)
- Bibliothèque de produits
En ligne (4)
- Espèces
Human (3)Mouse (1)
- Étiquette
His Tag (1)Fc Tag (1)His Tag & Avi Tag (2)
- Marqueur
Unconjugated (2)Biotin-labeled (2)
| Numéro de produit | Espèces | Système d'expression | Description du produit | Structure protéique | Pureté | Caractéristiques | Pré-commande/Commande |
|---|---|---|---|---|---|---|---|
HOT NK2-H82E3 |  Human | HEK293 | Biotinylated Human IL-12B / NKSF2 / p40 Protein, His,Avitag™ |  |  |  |  Ajouter au panier |
| Human | HEK293 | Human IL-12B / NKSF2 / p40 Protein, Fc Tag |  | | | Ajouter au panier | |
| Human | HEK293 | Human IL-12B / NKSF2 / p40 Protein, His Tag |  | | | Ajouter au panier | |
 Mouse | HEK293 | Biotinylated Mouse IL-12B / NKSF2 / p40 Protein, His,Avitag™ (MALS verified) |  | | | Ajouter au panier |
Quantité totale4
- 1
IL-12BContexte de la molécule
Interleukin-12 (IL12) is also known as natural killer cell stimulatory factor (NKSF), cytotoxic lymphocyte maturation factor (CLMF) , is a heterodimeric cytokine encoded by two separate genes, IL-12A (p35) and IL-12B (p40). IL12 is naturally produced by dendritic cells, macrophages and human B-lymphoblastoid cells (NC-37) in response to antigenic stimulation. IL-12 is involved in the differentiation of naive T cells into Th0 cells and plays an important role in the activities of natural killer cells and T lymphocytes.IL-12 also has anti-angiogenic activity, which means it can block the formation of new blood vessels.
Interleukin-12 subunit beta (IL12B) also known as NKSF2, CLMF2 and P40. Interleukin-12 subunit beta has been shown to interact with IL23. A large excess of monomeric IL12B is also secreted by the cells producing IL12, and exhibits no demonstrable biological activity. Overexpression of IL12B gene has been shown to be associated with the pathogenesis of multiple sclerosis. In addition, studies have revealed that the promoter polymorphism of this gene is implicated in the severity of atopic and non-atopic asthma in children.
IL-12BAlias de la molécule
IL12B,CLMF,CLMF2,NKSF,NKSF2,p40
Informations sur les médicaments cliniques
| Nom anglais | Code de recherche | Phase de R&D | Entreprise | Indication | Essai clinique |
|---|---|---|---|---|---|
| RO-7837195 | RO-7837195; RO7837195 | Phase 2 Clinical | Genentech Inc | Colitis, Ulcerative | Details |
| PF-07261271 | RG-6730; PF-07261271 | Phase 2 Clinical | Pfizer Inc | Inflammatory Bowel Diseases | Details |
Informations sur les médicaments commercialisés
| Nom anglais | Code de recherche | Phase de R&D | Entreprise | Plus ancien nom de marque | Pays d'approbation le plus ancien | Indication la plus ancienne | Société d'approbation la plus ancienne | Date d'approbation la plus ancienne | Indication | Essai clinique |
|---|---|---|---|---|---|---|---|---|---|---|
| Ustekinumab biosimilar (Bio-Thera) | BAT-2206 | Approved | Bio-Thera Solutions Ltd | STARJEMZA, Usymro | United States | Plaque psoriasis; Crohn Disease; Colitis, Ulcerative; Arthritis, Psoriatic | Bio-Thera Solutions Ltd | 2025-05-22 | Arthritis, Psoriatic; Autoimmune Diseases; Colitis, Ulcerative; Crohn Disease; Plaque psoriasis; Psoriasis | Details |
| Ustekinumab | C-340; CNTO-1275 | Approved | Johnson & Johnson Innovative Medicine | Stelara, 喜达诺 | United States | Plaque psoriasis | Janssen Biotech Inc | 2009-09-25 | Arthritis, Juvenile; Arthritis, Psoriatic; Colitis, Ulcerative; Common Variable Immunodeficiency; Crohn Disease; Dermatitis, Atopic; Dermatomyositis; Diabetes Mellitus, Type 1; Hidradenitis Suppurativa; Ichthyosis; Inflammatory Bowel Diseases; Liver Cirrhosis, Biliary; Lupus Erythematosus, Systemic; Multiple Sclerosis; Palmoplantar pustulosis; Pediatric Crohn's disease; Plaque psoriasis; Polymyositis; Pouchitis; Psoriasis; Sjogren's Syndrome; Spondylitis, Ankylosing; Takayasu Arteritis; Type I Leukocyte Adhesion Defect; Uveitis | Details |
| Ebdarokimab | AK-101; AK101 | Approved | 爱达罗 | Mainland China | Plaque psoriasis | Zhongshan Akeso Biopharma Co Ltd | 2025-04-15 | Arthritis, Psoriatic; Colitis, Ulcerative; Crohn Disease; Plaque psoriasis; Psoriasis | Details | |
| Ustekinumab Biosimilar(Celltrion) | CT-P43 | Approved | Celltrion Inc | Steqeyma, Steqeyma IV, Qoyvolma | Canada | Arthritis, Psoriatic; Crohn Disease; Plaque psoriasis | Celltrion Inc | 2024-08-01 | Arthritis, Psoriatic; Colitis, Ulcerative; Crohn Disease; Plaque psoriasis; Psoriasis | Details |
| Ustekinumab biosimilar (Biocon) | Bmab 1200 | Approved | Biocon Biologics Ltd | Yesintek | United States | Colitis, Ulcerative; Crohn Disease; Arthritis, Psoriatic | Biocon Biologics Inc | 2024-11-29 | Arthritis, Psoriatic; Colitis, Ulcerative; Crohn Disease; Plaque psoriasis; Psoriasis | Details |
| Ustekinumab biosimilar (Alvotech) | AVT04; AVT-04 | Approved | Alvotech hf | Jamteki, Uzpruvo, SELARSDI™, JamtekiTM, Ustekinumab BS (F) | Japan | Arthritis, Psoriatic; Psoriasis | Fuji Pharma Co Ltd | 2023-09-25 | Arthritis, Psoriatic; Colitis, Ulcerative; Crohn Disease; Plaque psoriasis; Psoriasis | Details |
| Ustekinumab biosimilar (Samsung Bioepis) | SB-17; SB17 | Approved | Samsung Bioepis Co Ltd | Pyzchiva, Eksunbi | EU | Crohn Disease; Colitis, Ulcerative | Samsung Bioepis Nl Bv | 2024-04-19 | Arthritis, Psoriatic; Colitis, Ulcerative; Crohn Disease; Gastrointestinal Diseases; Inflammation; Plaque psoriasis; Psoriasis; Rheumatic Diseases; Skin Diseases | Details |
| Ustekinumab biosimilar (Amgen) | ABP-654; AMG-654 | Approved | Amgen Inc | Wezlana, WEZLANA, wezenla, WEZENLA | United States | Crohn Disease; Colitis, Ulcerative; Arthritis, Psoriatic; Plaque psoriasis | Amgen Inc | 2023-10-31 | Arthritis, Psoriatic; Colitis, Ulcerative; Crohn Disease; Plaque psoriasis; Psoriasis | Details |
- Informations sur la molécule
- Liste de produits
- Informations sur les médicaments commercialisés
- Informations sur les médicaments cliniques